Designating February 28, 2026, As "rare Disease Day" In The State Of Delaware.
Summary
House Concurrent Resolution 93 designates February 28, 2026, as "Rare Disease Day" in Delaware. The resolution is primarily commemorative and awareness-focused: it recites statistics about the prevalence of rare diseases, the limited number of approved treatments, and the challenges faced by patients and families, including delayed diagnosis, difficulty finding specialists, and barriers to care.
The resolution also highlights examples of rare diseases such as Lissencephaly and Ehlers-Danlos Syndrome, and notes Delaware’s prior creation of a Rare Disease Advisory Council in 2023. It frames the observance as part of a broader effort to support advocacy, public education, and policy attention for rare disease communities, while encouraging participation from patients, caregivers, medical professionals, researchers, and companies developing orphan products.
Impact
HCR 93 does not amend the Delaware Code, create a new regulatory program, or appropriate funds. Its legal effect is limited to formally recognizing a day of observance in the state, but it may help elevate public awareness and reinforce the work of the Rare Disease Advisory Council and related advocacy efforts. The resolution is relevant to patients, caregivers, health care providers, researchers, and organizations involved in rare disease treatment and orphan drug development.
Sentiment
The overall sentiment around the resolution appears strongly supportive and noncontroversial. The bill’s findings emphasize compassion for affected families, the need for awareness, and the importance of research and access to treatment, and the voting history shows no recorded opposition in the Senate third reading vote. The absence of committee transcripts suggests there was little or no public dispute over the measure.
Contention
There is no evident substantive contention in the available record. Because the resolution is symbolic and declaratory rather than regulatory, it does not appear to have raised disagreements over mandates, costs, or legal changes. Any discussion would likely have centered on the value of awareness campaigns and the role of state government in supporting rare disease advocacy rather than on competing policy positions.